Correlation Between 23Andme Holding and Biohaven Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both 23Andme Holding and Biohaven Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 23Andme Holding and Biohaven Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 23Andme Holding Co and Biohaven Pharmaceutical Holding, you can compare the effects of market volatilities on 23Andme Holding and Biohaven Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 23Andme Holding with a short position of Biohaven Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of 23Andme Holding and Biohaven Pharmaceutical.

Diversification Opportunities for 23Andme Holding and Biohaven Pharmaceutical

-0.31
  Correlation Coefficient

Very good diversification

The 3 months correlation between 23Andme and Biohaven is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and Biohaven Pharmaceutical Holdin in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biohaven Pharmaceutical and 23Andme Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 23Andme Holding Co are associated (or correlated) with Biohaven Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biohaven Pharmaceutical has no effect on the direction of 23Andme Holding i.e., 23Andme Holding and Biohaven Pharmaceutical go up and down completely randomly.

Pair Corralation between 23Andme Holding and Biohaven Pharmaceutical

Allowing for the 90-day total investment horizon 23Andme Holding Co is expected to under-perform the Biohaven Pharmaceutical. In addition to that, 23Andme Holding is 1.94 times more volatile than Biohaven Pharmaceutical Holding. It trades about -0.08 of its total potential returns per unit of risk. Biohaven Pharmaceutical Holding is currently generating about 0.1 per unit of volatility. If you would invest  3,817  in Biohaven Pharmaceutical Holding on September 3, 2024 and sell it today you would earn a total of  784.00  from holding Biohaven Pharmaceutical Holding or generate 20.54% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

23Andme Holding Co  vs.  Biohaven Pharmaceutical Holdin

 Performance 
       Timeline  
23Andme Holding 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days 23Andme Holding Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Biohaven Pharmaceutical 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Biohaven Pharmaceutical Holding are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Biohaven Pharmaceutical displayed solid returns over the last few months and may actually be approaching a breakup point.

23Andme Holding and Biohaven Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with 23Andme Holding and Biohaven Pharmaceutical

The main advantage of trading using opposite 23Andme Holding and Biohaven Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 23Andme Holding position performs unexpectedly, Biohaven Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will offset losses from the drop in Biohaven Pharmaceutical's long position.
The idea behind 23Andme Holding Co and Biohaven Pharmaceutical Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm